Cheryl R. Blanchard - Mar 10, 2023 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role
President, CEO, Director, Director
Signature
/s/ Cheryl R. Blanchard
Stock symbol
ANIK
Transactions as of
Mar 10, 2023
Transactions value $
-$344,807
Form type
4
Date filed
3/14/2023, 04:46 PM
Previous filing
Mar 10, 2023
Next filing
Apr 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIK Common Stock Options Exercise $0 +30.1K +35.9% $0.00 114K Mar 10, 2023 Direct F1
transaction ANIK Common Stock Tax liability -$345K -13.2K -11.61% $26.10 101K Mar 10, 2023 Direct F2, F3
holding ANIK Common Stock 11.7K Mar 10, 2023 Revocable Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIK Restricted Stock Unit Options Exercise $0 -30.1K -33.33% $0.00 60.1K Mar 10, 2023 Common Stock 30.1K $0.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the first vesting installment of Restricted Stock Units (RSUs) granted on March 11, 2022.
F2 Reflects an aggregate of 13,211 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 11, 2023.
F3 Reflects the closing price of ANIK common stock on March 10, 2023, the trading day immediately preceding the date on which the vesting of RSUs gave rise to tax withholding obligations.
F4 Consists of shares transferred by Dr. Blanchard to The Cheryl R. Blanchard Amended and Restated Revocable Trust dated December 19, 2014, of which Dr. Blanchard is a beneficiary and the sole trustee.
F5 Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023.